FierceBiotech14d
Eli Lilly's next R&D focus: Testing incretin meds in neuro, immunology fields
Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...
FierceBiotech14d
UPDATED: Eli Lilly lops Alzheimer's and obesity assets from pipeline in Q4 update
In obesity, Lilly removed a dual amylin calcitonin receptor agonist (DACRA) from its phase 1 pipeline. Lilly got into DACRAs by partnering with KeyBioscience in 2017. At one time, the Big Pharma was ...
Weight-loss drug Zepbound helped drive Ireland to $76 billion in goods exports to the U.S. last year—a bittersweet reminder of the challenges ahead
Ireland's pharmaceutical industry shipped billions' worth of goods to the U.S., but face threats from Trump 2.0.
STAT14d
AstraZeneca offers some reassurance on China challenges
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. We get into more ...
Irish Examiner4d
What inspires American companies to choose to locate in Ireland?
Colm Greaves, a former tech sector executive and now a full-time journalist, revisits an MBA exam question that he faced some ...
pharmaphorum14d
Clinical trends for 2025: A year of change
After 2024, which saw a steady recovery by the life sciences industry, it looks like 2025 is set to be a year of change and ...
Hosted on MSN16d
Ireland's small, open economy is about to be put to the test
US president Donald Trump is moving ahead with threatened tariffs and Ireland's food and drink sectors could be a target ...